IFNα was the first cytokine approved for human cancer treatment (hairy cell leukemia; HCL) followed by approval of high-dose IL-2 (HDIL-2) for metastatic renal cell carcinoma (mRCC) and metastatic melanoma (MM). Here, IL2 is linked to hairy cell leukemia.